Skip to main content

In the News


August

License Granted to Cornell Startup, Angiocrine Bioscience, Inc., May Lead to New Therapies for Blood Disorders

Angiocrine Bioscience, a biotech company focused on applying vascular biology to new therapeutic applications and developer of the VeraVec™ technology platform, has licensed the rights to a new technology from Weill Cornell Medical College that converts a patient’s own endothelial cells directly into blood stem cells capable of treating a variety of diseases with fewer risks than using blood from a donor.

Adapt-N from Cornell Startup, Agronomic Technology Corporation, Reduces Emissions and Saves Crops

Adapt-N, a software program that assists farmers in determining how and when to apply nitrogen fertilizer to their fields, could help reduce greenhouse gas emissions, protect crops, and save farmers money.

Cornell Chemical Engineers Achieve Battery Breakthrough

In the race for safer, longer-lasting batteries to power the world’s automobiles, cell phones, computers, and autonomous robots, Cornell engineers have discovered a method to potentially extend the daily cycle life of a rechargeable lithium battery by up to a factor of 10.

Cornell Grapes in Two Winning Varietals at 2014 New York Wine & Food Classic

Lucas Vineyards’ 2013 Cayuga White took home “Best Cayuga” and 2013 Traminette from Thirsty Owl Wine Company took home “Best Traminette” at the 2014 New York Wine & Food Classic. Both ‘Cayuga White’ and ‘Traminette’ are wine grapes that were developed by Cornell’s grape breeding program. 

Cornell Tech's Rajit Manohar Helps Design IBM 'Brain Chip'

Manohar, associate dean for academic affairs at Cornell Tech and professor of electrical and computer engineering, pioneered the design methodology for a new IBM computer chip inspired by the human brain.

Relmada Therapeutics, Licensee of Cornell's D-methadone, Completes Company Name Change, Announces New Ticker

Relmada, a clinical-stage company developing novel therapies for the treatment of chronic pain including D-methadone from Cornell, has completed a name change from Camp Nine, Inc. to Relmada Therapeutics, Inc. and has been assigned a new trading symbol, RLMD.

Brush From Cornell Startup, Immunovent, LLC, May Replace Allergy Pricks

Immunovent has developed a less painful and possibly more accurate allergy test using a brush to collect cells from inside the cheek and nose and tests them with its Local Antibody Mucosal Brush Diagnostic (LAMB-Dx), a method which may replace uncomfortable and often unreliable prick tests.

Goose Watch Winery First in the Nation to Release 'Aromella' Wine

Goose Watch announces the release of 2013 Aromella, a varietal wine made from grapes developed at Cornell University. 2013 Aromella is an aromatic semi-dry white wine with distinctive characteristics that boasts some of the favored flavors from the Muscat grape used in the trending Moscatos such as peaches and tropical fruits, but with less sweetness.

Cornell Scientists Have Discovered A New Player in Lipid Metabolism

Researchers have discovered a novel function of a gene involved in the clearance of misfolded proteins in fat cells, SEL1L, showing that it also serves as a regulator of lipid metabolism.


July

Topological Spintronics from Cornell May Lead to More Efficient Computer Memory

Cornell physicists have discovered a new material combination, known as “topological insulators,” that can be 10 times more efficient for controlling magnetic memory or logic than any other combination of materials measured to date.

Cornell Startup, Novomer, Inc., Names Quimidroga S.A. an Authorized Distributor in Europe

Novomer, producers of low-cost, high performance sustainable polymers and other chemicals, has named Quimidroga as an authorized distributor of its Converge polypropylene carbonate polyols in Spain, Portugal, and Turkey for use in polyurethane formulations targeted at adhesive, coatings, sealants, elastomers and rigid and flexible foams.  

Cornell Startup, MetaStat, Inc., to Transfer Therapeutic Business to ASET Therapeutics

MetaStat, a life science company focused on understanding and treating systemic metastasis, announced that it entered into a Memorandum of Understanding (MOU) to transfer therapeutic assets (including licenses, personnel, and laboratory space) to newly formed ASET Therapeutics, leaving MetaStat to focus on being “a pure play diagnostic company with a platform of cancer diagnostics and companion biomarkers for multiple cancer indications.”

ChromaDex Initiates Human Clinical Trial of NIAGEN™, Based On Licensed Cornell Technology

ChromaDex Corp., a natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announce the initiation of the first human clinical study for its patented ingredient NIAGEN™, a commercially available form of nicotinamide riboside (NR), based on licensed Cornell technology.

Researchers from WCMC Reprogram Cells for Treating Blood Disorders

Weill Cornell Medical College researchers have directly reprogrammed vascular cells into long-lasting blood cells that resemble bone marrow stem cells capable of forming the various components of blood necessary for life and could eventually offer millions of patients with blood disorders curative therapies derived from their own cells.

Cornell Startup, MetaStat, Inc., Closes $5.7 Million Equity Financing

MetaStat, a life sciences company focused on understanding and treating systemic metastasis, announced that it has entered into a securities purchase agreement in a private placement totaling $5.7 million, which will enable the company to accelerate the development and commercialization of its cancer diagnostic platform.

Cornell Startup, GeneWeave Biosciences Inc., Attracts $12 Million to Provide Diagnostic Solutions for Multi-Drug-Resistant Organisms

GeneWeave, an in vitro diagnostics company that advances clinical microbiology with diagnostic solutions to prevent drug-resistant infections, announced the completion of its $12 million Series B financing to support clinical studies and commercialization of the company’s sample-in/susceptibility-out platform technology.

For archived news items, click here.